Skip to main content

Urticaria News

Research Highlights
01/29/2026
Rebecca Mashaw
New biologic agents and small-molecule therapies expanding options beyond traditional antihistamines and omalizumab.
New biologic agents and small-molecule therapies expanding options beyond traditional antihistamines and omalizumab.
New biologic agents and...
01/29/2026
Allergy & Immunology
Research Review
01/29/2026
Rebecca Mashaw
A recent review suggests that chronic urticaria may be a potential cutaneous clue to systemic autoinflammatory disease.
A recent review suggests that chronic urticaria may be a potential cutaneous clue to systemic autoinflammatory disease.
A recent review suggests that...
01/29/2026
Allergy & Immunology
Clinical Review
01/16/2026
Rebecca Mashaw
A recent review suggests that chronic urticaria may be a cutaneous clue to systemic autoinflammatory disease.
A recent review suggests that chronic urticaria may be a cutaneous clue to systemic autoinflammatory disease.
A recent review suggests that...
01/16/2026
Allergy & Immunology
News
12/06/2025
Jessica Garlewicz
New evidence suggests that blastocystis infection may contribute to immune dysregulation in urticaria through alterations in the intestinal microbiota.
New evidence suggests that blastocystis infection may contribute to immune dysregulation in urticaria through alterations in the intestinal microbiota.
New evidence suggests that...
12/06/2025
Allergy & Immunology
Population Analysis
12/06/2025
Jessica Garlewicz
The findings of an analysis underscore the potential role of common viral infections as a trigger for AU and offer insight into changing disease patterns during the COVID-19 pandemic.
The findings of an analysis underscore the potential role of common viral infections as a trigger for AU and offer insight into changing disease patterns during the COVID-19 pandemic.
The findings of an analysis...
12/06/2025
Allergy & Immunology
News
11/13/2025
Jessica Garlewicz
In a phase 2, randomized, double-blind trial, povorcitinib significantly reduced hives and itch severity in patients with chronic spontaneous urticaria refractory to second-generation H1-antihistamines.
In a phase 2, randomized, double-blind trial, povorcitinib significantly reduced hives and itch severity in patients with chronic spontaneous urticaria refractory to second-generation H1-antihistamines.
In a phase 2, randomized,...
11/13/2025
Allergy & Immunology